Search results
Results from the WOW.Com Content Network
These drugs act by binding the IL-2a receptor's α chain, preventing the IL-2 induced clonal expansion of activated lymphocytes and shortening their survival. They are used in the prophylaxis of the acute organ rejection after bilateral kidney transplantation, both being similarly effective and with only few side-effects. [citation needed]
prevention of organ transplant rejections, treatment of autoimmune diseases Cemiplimab [32] Libtayo: mab: human: PD-1: Y: cutaneous squamous cell carcinoma Cergutuzumab amunaleukin [12] mab: humanized: IL-2: cancer Certolizumab pegol [43] Cimzia: Fab' humanized: TNF-α: Y: Crohn's disease, rheumatoid arthritis, axial spondyloarthritis ...
Lymphoma and a variety of autoimmune diseases, although it may be ineffective in treating IgA-mediated diseases. [13] Cardiac arrest, cytokine release syndrome, tumor lysis syndrome and acute kidney injury, infections, [14] hepatitis B reactivation, immune toxicity, pulmonary toxicity, [15] bowel obstruction and perforation [16] [17] [18]
Additionally, it is used for treating graft-versus-host disease after a bone marrow transplant, or for the treatment of auto-immune diseases such as systemic lupus erythematosus, rheumatoid arthritis, Sjögren's syndrome, or Crohn's disease. This is typically done using medications, but may involve surgery (splenectomy), plasmapheresis, or ...
Monoclonal antibodies used for autoimmune diseases include infliximab and adalimumab, which are effective in rheumatoid arthritis, Crohn's disease and ulcerative colitis by their ability to bind to and inhibit TNF-α. [22] Basiliximab and daclizumab inhibit IL-2 on activated T cells and thereby help preventing acute rejection of kidney ...
CRS needs to be distinguished from symptoms of the disease itself and, in the case of drugs, from other adverse effects—for example tumor lysis syndrome requires different interventions. As of 2015, differential diagnoses depended on the judgement of doctor as there were no objective tests. [5]
Immunoglobulin therapy is the use of a mixture of antibodies (normal human immunoglobulin) to treat several health conditions. [13] [14] These conditions include primary immunodeficiency, immune thrombocytopenic purpura, chronic inflammatory demyelinating polyneuropathy, Kawasaki disease, certain cases of HIV/AIDS and measles, Guillain–Barré syndrome, and certain other infections when a ...
The primary use of IMiDs in medicine is in the treatment of cancers and autoimmune diseases (including one that is a response to the infection leprosy). [18] Indications for these agents that have received regulatory approval include: [19] Myelodysplastic syndrome, a precursor condition to acute myeloid leukaemia